Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1[1].
References
[1] Lord DM, et, al. Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody. MAbs. 2018 Apr;10(3):444-452. DOI:10.1080/19420862.2018.1426421